b'Source: Association of Treatment With Nirmatrelvir and the Risk of PostCOVID-19 Condition; JAMA Internal Medicine; www.ncbi.nlm.nih.gov/pmc/articles/PMC10037200/u From Page 106Nirmatrelvir was also associated with reduced risktreated persons between 30 to 180 days of infection.of post-acute death (HR, 0.53; 95% CI, 0.46-0.61);The researchers advised that their findings should ARR,0.65%;95%CI,0.54-0.77),andpost-acutebe contextualized within the broader body of evi-hospitalization (HR, 0.53; 95% CI, 0.46-0.61); ARR,dence showing effectiveness of nirmatrelvir in also 0.65%; 95% CI, 0.54-0.77), and postacute hospital- reducing risk of hospitalization or death in the acute ization (HR, 0.76; 95% CI, 0.73-0.80; ARR, 1.72%;phase. The clinical decision to initiate treatment with 95% CI, 1.42-2.01).nirmatrelvir should consider its overall effectiveness Theauthorsstatedthatthetotalityoffindingsin reducing burden of death and disease in both the suggests that treatment with nirmatrelvir during theacute and post-acute phases of COVID-19.acute phase of COVID-19 may reduce the risk ofIn July, the U.S. Food and Drug Administration revised post-acute adverse health outcomes. the Emergency Use Authorization (EUA) for Paxlovid The study noted that nirmatrelvir was associatedtoauthorizestate-licensedpharmaciststoprescribe with 26% less risk of PCC, 47% less risk of post- the drug to eligible patients, with certain limitations to acute death and 24% less risk of post-acute hospi- ensure appropriate patient assessment and prescribing. talization, adding, the magnitude of risk reduction1Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirma-on the absolute scale is also substantial amountingtrelvir and the Risk of PostCOVID-19 Condition. JAMA Intern to 4.51, 0.65, and 1.72 less cases of PCC, post-acuteMed. Published online March 23, 2023. doi:10.1001/jamain-death and post-acute hospitalization for every 100ternmed.2023.0743108'